Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434226
Status:
TERMINATED
Last Update Posted:
2009-08-21
First Post:
2007-02-11
Brief Title:
A Study of Sunitinib in Combination With Bevacizumab Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer SABRE-L
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Randomized Controlled Open-Label Multicenter Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Based on data collected the combination appeared to be poorly tolearated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II randomized controlled open-label multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC All patients will have advanced histologically or cytologically confirmed NSCLC Stage IIIb with pleural effusions Stage IV or recurrent
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None